2024年美國臨床腫瘤學會泌尿男生殖系腫瘤分會（ASCO-GU）年會將於當地時間2024年1月25日至27日在舊金山盛大召開。ASCO GU是泌尿男生殖系腫瘤領域的學術盛會，會議將展示該領域最具創新性的科學進展，並探討泌尿男生殖系腫瘤未來的治療方向。多項國外泌尿男生殖系腫瘤重磅研究即將公布，醫脈通精選整理如下，邀您一覽！
General Session
全體大會
0 1
摘要號：15
摘要號：15
標題：Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
講者：Neal D. Shore
時間：2024/1/25 GMT-8 14:30
0 2
摘要號：529
摘要號：529
標題：Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.
講者：Marie-Pier St-Laurent
時間：2024/1/26 GMT-8 13:50
0 3
摘要號：528
摘要號：528
標題：Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.
講者：Daniel M. Geynisman
時間：2024/1/26 GMT-8 15:20
Oral Abstract Session
口頭報告專場
0 4
摘要號：19
標題：BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
講者：Maha H. A. Hussain
時間：2024/1/25 GMT-8 08:15
0 5
摘要號：18
標題：CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
講者：Neeraj Agarwal
時間：2024/1/25 GMT-8 08:25
0 6
摘要號：260
標題：Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
講者：Karen E. Hoffman
時間：2024/1/25 GMT-8 08:57
0 7
摘要號：LBA530
標題：Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
講者：Michiel Simon Van Der Heijden
時間：2024/1/26 GMT-8 16：15
0 8
摘要號：539
標題：Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).
講者：Rohit K. Jain
時間：2024/1/26 GMT-8 16：25
0 9
摘要號：LBA531
標題：AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
講者：Andrea B. Apolo
時間：2024/1/26 GMT-8 16:47
10
摘要號：LBA358
標題：Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
講者：Robert J. Motzer
時間：2024/1/27 GMT-8 08:15
11
摘要號：LBA359
標題：Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
講者：Toni K. Choueiri
時間：2024/1/27 GMT-8 08:25
12
摘要號：LBA360
標題：Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
講者：Saby George
時間：2024/1/27 GMT-8 08:47
13
摘要號：LBA361
摘要號：LBA361
標題：Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
講者：Thomas Powles
時間：2024/1/27 GMT-8 08:57
Rapid Oral Abstract Session
快速口頭報告專場
14
摘要號：20
標題：Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.
講者：Amit Bahl
時間：2024/1/25 GMT-8 16:15
15
摘要號：121
標題：Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
講者：Himisha Beltran
時間：2024/1/25 GMT-8 16:25
16
摘要號：537
標題：Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study
講者：Amanda Nizam
時間：2024/1/26 GMT-8 07:50
17
摘要號：534
標題：Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
講者：Matthew Nicholas Young
時間：2024/1/26 GMT-8 08:05
18
摘要號：632
標題：Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial.
講者：Matt D. Galsky
時間：2024/1/26 GMT-8 08：15
19
摘要號：362
標題：Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
講者：Maria Teresa Bourlon
時間：2024/1/27 GMT-8 13:00
20
摘要號：363
標題：Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
講者：Nizar M. Tannir
時間：2024/1/27 GMT-8 13:05
21
摘要號：364
標題：Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial.
講者：Viktor Grünwald
時間：2024/1/27 GMT-8 13:10
22
摘要號：1
標題：Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
講者：Enrique Grande
時間：2024/1/27 GMT-8 13:20
備註：排名不分先後，按照匯報時間進行排序
若您有感興趣的研究，請留言告知我們，待會議摘要內容公布，我們將對其進行詳細解讀~
編輯：Gardenia
審校：Gardenia
執行：Gardenia
本平台旨在為醫療衛生專業人士傳遞更多醫學資訊。本平台釋出的內容，不能以任何方式取代專業的醫療指導，也不應被視為診療建議。如該等資訊被用於了解醫學資訊以外的目的，本平台不承擔相關責任。本平台對釋出的內容，並不代表同意其描述和觀點。若涉及版權問題，煩請權利人與我們聯系，我們將盡快處理。
醫脈通是專業的線上醫生平台，「感知世界醫學脈搏，助力中國臨床決策」是平台的使命。 醫脈通旗下擁有「臨床指南」「用藥參考」「醫學文獻王」「醫知源」「e研通」「e脈播」等系列產品，全面滿足醫學工作者臨床決策、獲取新知及提升科研效率等方面的需求。
